A Phase 1 Parallel Open-Label Study of the Safety and Tolerability Pharmacokinetics and Antileukemic Activity of ASTX660 as a Single Agent and in Combination with ASTX727 in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Acute Myeloid Leukemia
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Have a projected life expectancy of at least 12 weeks, as assessed by the investigator. 2) Have histological confirmation of AML by WHO 2016 criteria and are either: a. Unfit to be treated with intensive induction chemotherapy OR b. Refractory to intensive induction chemotherapy OR c. Relapsed after intensive induction chemotherapy or stem cell transplant.
You may not be eligible for this study if the following are true:
-
1) Known clinically active central nervous system (CNS) leukemia. 2) BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis). 3) Diagnosis of acute promyelocytic leukemia (M3 AML or APML).
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
